about
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base.Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin.Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.HER2 as a target in invasive urothelial carcinoma.Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II studySEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.New advances in genitourinary cancer: evidence gathered in 2014.Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).Curative radiation therapy for very elderly bladder cancer patients with localized disease.Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.SEOM clinical guideline for treatment of kidney cancer (2017).Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlledSNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.Comparative Efficacy And Costs Of Treatment Sequences In Metastatic Castration Resistant Prostate Cancer.Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyFrequent dose delays and growth factor requirements with the sequential doxorubicin-CMF scheduleAnalysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 statusPrognostic and Predictive Factors for Renal Cell CarcinomaSEOM clinical guideline thyroid cancer (2019)
P50
Q30382892-3112A69B-E3F0-484F-A979-2343CCDB022EQ30797642-DAC4887D-60A8-4DEB-8BDE-6DF464A647B6Q33334087-52B628AC-471D-4C77-AE76-911E6A0C42B8Q33417201-80417681-F730-4829-9B18-A56CCDB22D71Q33500435-61648DA9-8D15-4B3A-9F44-351216937140Q34603070-7BF95E48-0A93-442D-B167-33CE83E84978Q35755382-B6882A28-F37E-45E8-AEC2-E000FAE786EFQ35932363-A755374A-D033-4B4B-9ECF-E538FBE5EDDDQ36611472-09E2F79E-E1DB-4246-B43F-001EB0BA6D9DQ37475193-21B47E1E-B2B0-471F-8378-59D66802A2C9Q37514211-4F0D36CA-C59D-4991-A5E5-6AB7686DA0EEQ38017979-14BC082A-3EB6-4DB9-B4D2-D209CA9D74C7Q38188423-9B6118ED-20A7-4B80-92C9-F56B992EF313Q38557894-913CD25F-34E3-48B0-9A9A-51CAB2E4C775Q38585638-A9C7CFA8-0CA6-405C-A295-D6B15CB478FCQ38768663-131D88F4-E3E0-4C5A-8EE1-B81F6CA971A3Q38804089-3FA50001-1AB7-4C85-B50A-C5AF4392CFE5Q38864454-494F58D6-6603-4CA7-BB99-F24B9586AA61Q39012618-7BE7FD85-3499-47D2-8211-B4051E7603F1Q39252806-F8AF83E1-D04D-40EC-92FA-9B8F34308A29Q41897121-EAD76FAA-A2DF-4115-B3E2-45DF21A4D497Q44247719-55245D11-E235-4CE9-B434-B52C96FDB3D3Q44660503-0F7AF684-ACE1-4046-A4AD-3FC17559A997Q45939697-C8B1DAC8-8565-408A-8372-2FBC33F53F7CQ46348584-C14421C9-F2CB-44AB-9709-B5444A4B302FQ48265599-4753EC3D-4130-4D04-88E9-2AC5EA768F72Q48276400-8F9EDCF2-2E94-4B59-A268-2E1002A84DF2Q48310227-A0ED94A7-FF01-4508-BFFD-E86C747854C0Q50969589-86991D4F-1536-440F-BB72-E10D08FB49D0Q52882813-3BA44A54-8CEC-4262-8568-928E591FC652Q53135936-DDFC167D-1128-4D36-88B9-3806A785B885Q53236575-D8962CFD-E4A0-41A5-BD2F-6F2C964F87C6Q53810644-99AE4696-83EC-403C-ABD4-56E8DA3B47B5Q54145971-BDD43749-A908-4811-B1C6-123E344600ABQ60895639-60C03F10-52A4-4852-8F51-DF9A77F55989Q74268052-7CDAC63D-D9B0-4DC0-A535-21ACFFFA5E2BQ80350039-CBEB71C0-DC8B-416E-BFED-1C71E2CD84EAQ88142151-7342B394-8C9B-4614-A957-154E147B85E5Q89477253-BC16FCC0-D493-4A48-8D5B-3A00B1D40CE2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Enrique Gallardo
@ast
Enrique Gallardo
@en
Enrique Gallardo
@es
Enrique Gallardo
@nl
Enrique Gallardo
@sl
type
label
Enrique Gallardo
@ast
Enrique Gallardo
@en
Enrique Gallardo
@es
Enrique Gallardo
@nl
Enrique Gallardo
@sl
prefLabel
Enrique Gallardo
@ast
Enrique Gallardo
@en
Enrique Gallardo
@es
Enrique Gallardo
@nl
Enrique Gallardo
@sl
P106
P21
P31
P496
0000-0002-1375-3488